154 related articles for article (PubMed ID: 38529710)
21. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
[TBL] [Abstract][Full Text] [Related]
22. Sublingual Immunotherapy Tablets Relieve Symptoms in Adults with Allergic Rhinitis: A Meta-analysis of Randomized Clinical Trials.
Li Y; Yu SY; Tang R; Zhao ZT; Sun JL
Chin Med J (Engl); 2018 Nov; 131(21):2583-2588. PubMed ID: 30381592
[TBL] [Abstract][Full Text] [Related]
23. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases.
Nolte H; Maloney J
Allergol Int; 2018 Jul; 67(3):301-308. PubMed ID: 29759659
[TBL] [Abstract][Full Text] [Related]
24. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
[TBL] [Abstract][Full Text] [Related]
25. Sublingual immunotherapy in children: the recent experiences.
Pleskovic N; Bartholow A; Skoner DP
Curr Opin Allergy Clin Immunol; 2014 Dec; 14(6):582-90. PubMed ID: 25188717
[TBL] [Abstract][Full Text] [Related]
26. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents.
Matsuoka T; Bernstein DI; Masuyama K; Nolte H; Okamiya K; Seitzberg D; Nelson HS
Pediatr Allergy Immunol; 2017 Nov; 28(7):661-667. PubMed ID: 28660739
[TBL] [Abstract][Full Text] [Related]
27. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
Demoly P; Kleine-Tebbe J; Rehm D
Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339
[TBL] [Abstract][Full Text] [Related]
28. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
29. Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma.
Maloney J; Durham S; Skoner D; Dahl R; Bufe A; Bernstein D; Murphy K; Waserman S; Berman G; White M; Kaur A; Nolte H
Allergy; 2015 Mar; 70(3):302-9. PubMed ID: 25495666
[TBL] [Abstract][Full Text] [Related]
30. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
Richards JR; Stumpf JL
Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
[TBL] [Abstract][Full Text] [Related]
31. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
[TBL] [Abstract][Full Text] [Related]
32. Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis.
Devillier P; Wahn U; Zielen S; Heinrich J
Expert Rev Clin Immunol; 2017 Dec; 13(12):1199-1206. PubMed ID: 29072507
[TBL] [Abstract][Full Text] [Related]
33. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.
Dahl R; Roberts G; de Blic J; Canonica GW; Kleine-Tebbe J; Nolte H; Lawton S; Nelson HS
Allergy Asthma Proc; 2016; 37(2):92-104. PubMed ID: 26802643
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children.
Masuyama K; Okamoto Y; Okamiya K; Azuma R; Fujinami T; Riis B; Ohashi-Doi K; Natsui K; Imai T; Okubo K
Allergy; 2018 Dec; 73(12):2352-2363. PubMed ID: 30043449
[TBL] [Abstract][Full Text] [Related]
35. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
Meteran H; Backer V
Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
[No Abstract] [Full Text] [Related]
36. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.
Bernstein DI; Kleine-Tebbe J; Nelson HS; Bardelas JA; Sussman GL; Lu S; Rehm D; Svanholm Fogh B; Nolte H
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):105-110. PubMed ID: 29656145
[TBL] [Abstract][Full Text] [Related]
37. Update on house dust mite immunotherapy: are more studies needed?
Nelson HS
Curr Opin Allergy Clin Immunol; 2014 Dec; 14(6):542-8. PubMed ID: 25115684
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial.
Nolte H; Bernstein DI; Nelson HS; Ellis AK; Kleine-Tebbe J; Lu S
J Allergy Clin Immunol Pract; 2020; 8(7):2322-2331.e5. PubMed ID: 32304832
[TBL] [Abstract][Full Text] [Related]
39. Sublingual immunotherapy for asthma.
Normansell R; Kew KM; Bridgman AL
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD011293. PubMed ID: 26315994
[TBL] [Abstract][Full Text] [Related]
40. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
Mösges R; Ritter B; Kayoko G; Allekotte S
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
